The Principles of Engineering Immune Cells to Treat Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28187291.
- Also identified by DOI 10.1016/j.cell.2017.01.016 and PMC identifier 5553442.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.
Medical subject headings
- Neoplasms
- Receptors, Antigen, T-Cell
- T-Lymphocytes